Erste Group Bank Has Positive View of Sanofi FY2026 Earnings

Key Points

• Erste Group Bank raised its FY2026 EPS estimate for Sanofi to $4.92 (from $4.91) and forecasts FY2027 EPS of $5.23, versus a consensus FY2026 EPS of $4.36.
• Analyst coverage is mixed with an average rating of "Hold" and an average target price of $61.50; the street breakdown is 1 Strong Buy, 5 Buy, 7 Hold and 1 Sell.
• Sanofi shares opened at $47.14, with a market cap of $114.97 billion, a P/E of 13.09 and a 52‑week range of $43.32–$55.73, and institutional investors hold about 14.03% of the stock.

Sanofi (NASDAQ:SNY - Free Report) - Erste Group Bank increased their FY2026 earnings estimates for shares of Sanofi in a note issued to investors on Thursday, April 2nd. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $4.92 for the year, up from their previous estimate of $4.91. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Erste Group Bank also issued estimates for Sanofi's FY2027 earnings at $5.23 EPS.

A number of other analysts also recently issued reports on SNY. Weiss Ratings downgraded shares of Sanofi from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, March 23rd. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sanofi in a report on Friday, January 16th. Barclays downgraded shares of Sanofi from an "overweight" rating to an "equal weight" rating in a report on Tuesday, January 6th. UBS Group reiterated a "neutral" rating on shares of Sanofi in a report on Friday, January 16th. Finally, HSBC reiterated a "buy" rating on shares of Sanofi in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Sanofi presently has an average rating of "Hold" and an average target price of $61.50.

Sanofi Stock Performance

Shares of SNY stock opened at $47.14 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The company has a market capitalization of $114.97 billion, a P/E ratio of 13.09, a price-to-earnings-growth ratio of 1.19 and a beta of 0.42. The company's 50 day moving average price is $46.46 and its two-hundred day moving average price is $48.01. Sanofi has a 52 week low of $43.32 and a 52 week high of $55.73.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently modified their holdings of the stock. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi in the fourth quarter valued at $25,000. Financial Consulate Inc. bought a new stake in Sanofi during the third quarter worth about $26,000. Measured Wealth Private Client Group LLC bought a new stake in Sanofi during the third quarter worth about $29,000. Palisade Asset Management LLC bought a new stake in Sanofi during the third quarter worth about $30,000. Finally, First Horizon Corp bought a new stake in Sanofi during the third quarter worth about $33,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.